Generate Biomedicines, Inc. Common Stock (GENB) — Financial Flexibility Index
Generate Biomedicines, Inc. Common Stock (GENB) has a Financial Flexibility Index of -0.69x as of March 2026. Free cash flow of $-76.61 Million (operating CF $-80.39 Million minus capex $3.78 Million) represents -1% of total liabilities ($110.94 Million). Check GENB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Generate Biomedicines, Inc. Common Stock Financial Flexibility Index (2024–2025)
Historical Financial Flexibility Index trend for Generate Biomedicines, Inc. Common Stock across 2 annual periods. See working capital to net assets of Generate Biomedicines, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Generate Biomedicines, Inc. Common Stock (2024–2025)
Year-by-year free cash flow to debt coverage for Generate Biomedicines, Inc. Common Stock. For the full company profile including market capitalisation, see GENB market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.21x | $-197.10 Million | $-200.62 Million | $953.38 Million | ▼ -72.4% |
| 2024 | -0.12x | $-114.30 Million | $-117.75 Million | $953.35 Million | — |